Trajectory of Viral RNA Load Among Persons With Incident SARS-CoV-2 G614 Infection (Wuhan Strain) in Association With COVID-19 Symptom Onset and Severity | Infectious Diseases | JN Learning | AMA Ed Hub [Skip to Content]
Outline
Claim CME
PDF
Infectious Diseases

Trajectory of Viral RNA Load Among Persons With Incident SARS-CoV-2 G614 Infection (Wuhan Strain) in Association With COVID-19 Symptom Onset and Severity

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME
JAMA Network Open
January 10, 2022
Original Investigation
Helen C. Stankiewicz Karita, MD, MSc1;
Tracy Q. Dong, PhD2;
Christine Johnston, MD, MPH1,2,3;
Kathleen M. Neuzil, MD4;
Michael K. Paasche-Orlow, MD, MA, MPH5,6;
Patricia J. Kissinger, PhD, MPH7;
Anna Bershteyn, PhD8;
Lorna E. Thorpe, PhD8;
Meagan Deming, MD, PhD4;
Angelica Kottkamp, MD9;
Miriam Laufer, MD, MPH4,10;
Raphael J. Landovitz, MD, MSc11;
Alfred Luk, MD12;
Risa Hoffman, MD10;
Pavitra Roychoudhury, PhD2,3;
Craig A. Magaret, MS2,3;
Alexander L. Greninger, MD, PhD, MS, MPhil2,3;
Meei-Li Huang, PhD2;
Keith R. Jerome, MD, PhD2,3;
Mark Wener, MD3,13;
Connie Celum, MD, MPH1,14,15;
Helen Y. Chu, MD, MPH1,14,15;
Jared M. Baeten, MD, PhD1,14,15;
Anna Wald, MD, MPH1,2,3,15;
Ruanne V. Barnabas, MBChB, DPhil1,14,15;
Elizabeth R. Brown, ScD2,16,17
Author Affiliations
  • 1Division of Allergy and Infectious Diseases, University of Washington, Seattle
  • 2Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
  • 3Department of Laboratory Medicine and Pathology, University of Washington, Seattle
  • 4Department of Medicine, University of Maryland School of Medicine, Baltimore
  • 5Department of Medicine, Boston University School of Medicine, Boston, Massachusetts
  • 6Department of Medicine, Boston Medical Center, Boston, Massachusetts
  • 7Department of Epidemiology, Tulane University, New Orleans, Louisiana
  • 8Department of Population Health, New York University Grossman School of Medicine, New York
  • 9Department of Medicine, New York University Grossman School of Medicine, New York
  • 10Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore
  • 11Department of Medicine, University of California, Los Angeles, Los Angeles
  • 12Department of Medicine, Tulane University, New Orleans, Louisiana
  • 13Division of Rheumatology, University of Washington, Seattle
  • 14Department of Global Health, University of Washington, Seattle
  • 15Department of Epidemiology, University of Washington, Seattle
  • 16Department of Biostatistics, University of Washington, Seattle
  • 17Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
Read article on JAMA Network

MOC/CME Information

editorial comment icon
Editorial
Comment
 related articles icon
Related
Articles
 author interview icon
Interviews
 multimedia icon
Multimedia
Read Article Claim CME
Key Points

Question  What are the characteristics of SARS-CoV-2 G614 viral shedding in incident infections in association with COVID-19 symptom onset and severity?

Findings  In a cohort study of persons who tested positive for SARS-CoV-2 after recent exposure, viral RNA trajectory was characterized by a rapid peak followed by slower decay. Peak viral load correlated positively with symptom severity and generally occurred within 1 day of symptom onset if the patient was symptomatic.

Meaning  A detailed description of the SARS-CoV-2 G614 viral shedding trajectory serves as a baseline for comparison with new viral variants of concern and informs models to plan clinical trials to end the pandemic.

Abstract

Importance  The SARS-CoV-2 viral trajectory has not been well characterized in incident infections. These data are needed to inform natural history, prevention practices, and therapeutic development.

Objective  To characterize early SARS-CoV-2 viral RNA load (hereafter referred to as viral load) in individuals with incident infections in association with COVID-19 symptom onset and severity.

Design, Setting, and Participants  This prospective cohort study was a secondary data analysis of a remotely conducted study that enrolled 829 asymptomatic community-based participants recently exposed (<96 hours) to persons with SARS-CoV-2 from 41 US states from March 31 to August 21, 2020. Two cohorts were studied: (1) participants who were SARS-CoV-2 negative at baseline and tested positive during study follow-up, and (2) participants who had 2 or more positive swabs during follow-up, regardless of the initial (baseline) swab result. Participants collected daily midturbinate swab samples for SARS-CoV-2 RNA detection and maintained symptom diaries for 14 days.

Exposure  Laboratory-confirmed SARS-CoV-2 infection.

Main Outcomes and Measures  The observed SARS-CoV-2 viral load among incident infections was summarized, and piecewise linear mixed-effects models were used to estimate the characteristics of viral trajectories in association with COVID-19 symptom onset and severity.

Results  A total of 97 participants (55 women [57%]; median age, 37 years [IQR, 27-52 years]) developed incident infections during follow-up. Forty-two participants (43%) had viral shedding for 1 day (median peak viral load cycle threshold [Ct] value, 38.5 [95% CI, 38.3-39.0]), 18 (19%) for 2 to 6 days (median Ct value, 36.7 [95% CI, 30.2-38.1]), and 31 (32%) for 7 days or more (median Ct value, 18.3 [95% CI, 17.4-22.0]). The cycle threshold value has an inverse association with viral load. Six participants (6%) had 1 to 6 days of viral shedding with censored duration. The peak mean (SD) viral load was observed on day 3 of shedding (Ct value, 33.8 [95% CI, 31.9-35.6]). Based on the statistical models fitted to 129 participants (60 men [47%]; median age, 38 years [IQR, 25-54 years]) with 2 or more SARS-CoV-2–positive swab samples, persons reporting moderate or severe symptoms tended to have a higher peak mean viral load than those who were asymptomatic (Ct value, 23.3 [95% CI, 22.6-24.0] vs 30.7 [95% CI, 29.8-31.4]). Mild symptoms generally started within 1 day of peak viral load, and moderate or severe symptoms 2 days after peak viral load. All 535 sequenced samples detected the G614 variant (Wuhan strain).

Conclusions and Relevance  This cohort study suggests that having incident SARS-CoV-2 G614 infection was associated with a rapid viral load peak followed by slower decay. COVID-19 symptom onset generally coincided with peak viral load, which correlated positively with symptom severity. This longitudinal evaluation of the SARS-CoV-2 G614 with frequent molecular testing serves as a reference for comparing emergent viral lineages to inform clinical trial designs and public health strategies to contain the spread of the virus.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

See More About

Infectious Diseases Coronavirus (COVID-19)
Article Information

Accepted for Publication: November 14, 2021.

Published: January 10, 2022. doi:10.1001/jamanetworkopen.2021.42796

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Stankiewicz Karita HC et al. JAMA Network Open.

Corresponding Author: Helen C. Stankiewicz Karita, MD, Division of Allergy and Infectious Diseases, University of Washington, 325 Ninth Ave, Mailstop 359928, Seattle, WA 98104 (helensk@uw.edu).

Author Contributions: Drs Barnabas and Brown had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Stankiewicz Karita and Dong contributed equally to this work as co–first authors.

Concept and design: Stankiewicz Karita, Dong, Neuzil, Thorpe, Deming, Celum, Chu, Baeten, Wald, Brown.

Acquisition, analysis, or interpretation of data: Stankiewicz Karita, Dong, Johnston, Neuzil, Paasche-Orlow, Kissinger, Bershteyn, Thorpe, Kottkamp, Laufer, Landovitz, Luk, Hoffman, Roychoudhury, Magaret, Greninger, Huang, Jerome, Wener, Chu, Baeten, Wald, Barnabas, Brown.

Drafting of the manuscript: Stankiewicz Karita, Dong, Kissinger, Kottkamp, Wald, Brown.

Critical revision of the manuscript for important intellectual content: Stankiewicz Karita, Dong, Johnston, Neuzil, Paasche-Orlow, Kissinger, Bershteyn, Thorpe, Deming, Kottkamp, Laufer, Landovitz, Luk, Hoffman, Roychoudhury, Magaret, Greninger, Huang, Jerome, Wener, Celum, Chu, Baeten, Wald, Barnabas.

Statistical analysis: Dong, Magaret, Wald, Brown.

Obtained funding: Jerome, Celum, Baeten, Barnabas.

Administrative, technical, or material support: Stankiewicz Karita, Paasche-Orlow, Deming, Kottkamp, Laufer, Luk, Hoffman, Roychoudhury, Greninger, Huang, Jerome, Wener, Chu, Baeten, Wald.

Supervision: Johnston, Bershteyn, Thorpe, Kottkamp, Laufer, Roychoudhury, Greninger, Jerome, Chu, Baeten, Wald, Barnabas, Brown.

Conflict of Interest Disclosures: Dr Stankiewicz Karita reported receiving grants from the Bill & Melinda Gates Foundation and the National Cancer Institute at the National Institutes of Health (NIH) during the conduct of the study. Dr Dong reported receiving grants from the Bill & Melinda Gates Foundation during the conduct of the study. Dr Johnston reported receiving royalties from UpToDate; personal fees from AbbVie, Gilead, and MedPace; and grants from the Bill & Melinda Gates Foundation outside the submitted work. Dr Neuzil reported receiving grants from Pfizer grant to her institution for a COVID-19 vaccine trial during the conduct of the study. Dr Bershteyn reported receiving grants from the Bill & Melinda Gates Foundation during the conduct of the study; grants from the NIH and the New York City Department of Health and Mental Hygiene; and personal fees from Gates Ventures outside the submitted work. Dr Landovitz reported serving on the scientific advisory board for Gilead Sciences and Merck Inc; and receiving honoraria for conference presentations from Janssen and Cepheid outside the submitted work. Dr Luk reported receiving grants from the Bill & Melinda Gates Foundation during the conduct of the study. Dr Magaret reported receiving personal fees from Prevencio Inc outside the submitted work. Dr Greninger reported having a contract from Abbott Molecular; receiving grants from Merck; and receiving grants from Gilead outside the submitted work. Dr Wener reported receiving grants from the Bill & Melinda Gates Foundation during the conduct of the study. Dr Celum reported receiving personal fees from Merck and Gilead outside the submitted work. Dr Chu reported receiving grants from the Bill & Melinda Gates Foundation during the conduct of the study; personal fees from Ellume, Merck, the Bill & Melinda Gates Foundation, Pfizer, and Glaxo Smith Kline; grants from Gates Ventures and Sanofi Pasteur; and reagents from from Cepheid and Ellume outside the submitted work. Dr Baeten reported receiving grants from the Bill & Melinda Gates Foundation during the conduct of the study; and being an employee of Gilead Sciences outside the submitted work. Dr Wald reported receiving grants from the Bill & Melinda Gates Foundation during the conduct of the study; nonfinancial support from Merck; personal fees from Aicuris, X-Vax, Crozet, and Auritec; and grants from GSK and Sanofi outside the submitted work. Dr Barnabas reported receiving grants from the NIH and the Bill & Melinda Gates Foundation during the conduct of the study; and nonfinancial support from Regeneron Pharmaceuticals outside the submitted work. Dr Brown reported receiving grants from the Bill & Melinda Gates Foundation during the conduct of the study; and grants from the NIH; and personal fees from Merck outside the submitted work. No other disclosures were reported.

Funding/Support: This study was supported by award INV-016204 from the Bill and Melinda Gates Foundation. Dr Stankiewicz Karita is funded by the Research Supplement from the National Cancer Institute at the NIH (grant R01 CA213130-S) and the Department of Medicine Diversity Academic Development Scholar Award at the University of Washington. Dr Deming is funded by the Infectious Diseases Clinical Research Consortium through the National Institute for Allergy and Infectious Diseases of the NIH, under award number UM1AI148684.

Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

References
1.
World Health Organization. COVID-19 vaccines. Accessed June 25, 2021. https://www.who.int/teams/regulation-prequalification/eul/covid-19
2.
Ritchie  H , Mathieu  E , Rodés-Guirao  L ,  et al. Coronavirus Pandemic (COVID-19). Our World in Data. Accessed June 25, 2021. https://ourworldindata.org/coronavirus
3.
Volz  E , Mishra  S , Chand  M ,  et al; COVID-19 Genomics UK (COG-UK) consortium.  Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England.   Nature. 2021;593(7858):266-269. doi:10.1038/s41586-021-03470-x PubMedGoogle ScholarCrossref
4.
Tegally  H , Wilkinson  E , Giovanetti  M ,  et al.  Detection of a SARS-CoV-2 variant of concern in South Africa.   Nature. 2021;592(7854):438-443. doi:10.1038/s41586-021-03402-9 PubMedGoogle ScholarCrossref
5.
Davies  NG , Abbott  S , Barnard  RC ,  et al; CMMID COVID-19 Working Group; COVID-19 Genomics UK (COG-UK) Consortium.  Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England.   Science. 2021;372(6538):eabg3055. doi:10.1126/science.abg3055 PubMedGoogle Scholar
6.
European Centre for Disease Prevention and Control. SARS-CoV-2 variants of concern as of 18 November 2021. Accessed July 5, 2021. https://www.ecdc.europa.eu/en/covid-19/variants-concern
7.
Centers for Disease Control and Prevention. SARS-CoV-2 variant classifications and definitions. Accessed July 5, 2021. https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html
8.
World Health Organization. Tracking SARS-CoV-2 variants. Accessed July 5, 2021. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
9.
Centers for Disease Control and Prevention. COVID data tracker. Accessed July 10, 2021. https://covid.cdc.gov/covid-data-tracker/#variant-proportions
10.
Walsh  KA , Jordan  K , Clyne  B ,  et al.  SARS-CoV-2 detection, viral load and infectivity over the course of an infection.   J Infect. 2020;81(3):357-371. doi:10.1016/j.jinf.2020.06.067 PubMedGoogle ScholarCrossref
11.
Li  N , Wang  X , Lv  T .  Prolonged SARS-CoV-2 RNA shedding: not a rare phenomenon.   J Med Virol. 2020;92(11):2286-2287. doi:10.1002/jmv.25952 PubMedGoogle ScholarCrossref
12.
Wölfel  R , Corman  VM , Guggemos  W ,  et al.  Virological assessment of hospitalized patients with COVID-2019.   Nature. 2020;581(7809):465-469. doi:10.1038/s41586-020-2196-x PubMedGoogle ScholarCrossref
13.
Zou  L , Ruan  F , Huang  M ,  et al.  SARS-CoV-2 viral load in upper respiratory specimens of infected patients.   N Engl J Med. 2020;382(12):1177-1179. doi:10.1056/NEJMc2001737 PubMedGoogle ScholarCrossref
14.
Lewis  NM , Duca  LM , Marcenac  P ,  et al.  Characteristics and timing of initial virus shedding in severe acute respiratory syndrome coronavirus 2, Utah, USA.   Emerg Infect Dis. 2021;27(2):352-359. doi:10.3201/eid2702.203517 PubMedGoogle ScholarCrossref
15.
Han  MS , Choi  EH , Chang  SH ,  et al.  Clinical characteristics and viral RNA detection in children with coronavirus disease 2019 in the Republic of Korea.   JAMA Pediatr. 2021;175(1):73-80. doi:10.1001/jamapediatrics.2020.3988 PubMedGoogle ScholarCrossref
16.
Barnabas  RV , Brown  ER , Bershteyn  A ,  et al; Hydroxychloroquine COVID-19 PEP Study Team.  Hydroxychloroquine as postexposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 infection: a randomized trial.   Ann Intern Med. 2021;174(3):344-352. doi:10.7326/M20-6519 PubMedGoogle ScholarCrossref
17.
Harris  PA , Taylor  R , Minor  BL ,  et al; REDCap Consortium.  The REDCap consortium: building an international community of software platform partners.   J Biomed Inform. 2019;95:103208. doi:10.1016/j.jbi.2019.103208 PubMedGoogle Scholar
18.
Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): 2020 interim case definition, approved August 5, 2020. Accessed January 10, 2021. https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-2019-2020-08-05/
19.
Lieberman  JA , Pepper  G , Naccache  SN , Huang  ML , Jerome  KR , Greninger  AL .  Comparison of commercially available and laboratory-developed assays for in vitro detection of SARS-CoV-2 in clinical laboratories.   J Clin Microbiol. 2020;58(8):e00821-20. doi:10.1128/JCM.00821-20 PubMedGoogle Scholar
20.
Addetia  A , Lin  MJ , Peddu  V , Roychoudhury  P , Jerome  KR , Greninger  AL .  Sensitive recovery of complete SARS-CoV-2 genomes from clinical samples by use of Swift Biosciences’ SARS-CoV-2 multiplex amplicon sequencing panel.   J Clin Microbiol. 2020;59(1):e02226-20. doi:10.1128/JCM.02226-20 PubMedGoogle Scholar
21.
Gottlieb  RL , Nirula  A , Chen  P ,  et al.  Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial.   JAMA. 2021;325(7):632-644. doi:10.1001/jama.2021.0202 PubMedGoogle ScholarCrossref
22.
Weinreich  DM , Sivapalasingam  S , Norton  T ,  et al; Trial Investigators.  REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19.   N Engl J Med. 2021;384(3):238-251. doi:10.1056/NEJMoa2035002 PubMedGoogle ScholarCrossref
23.
Therneau  TM , Grambsch  PM . The Cox model BT—modeling survival data: extending the Cox model. In: Dietz K, Gail M, Krickeberg K, Samet J, and Tsiatis A, eds.  Statistics for Biology and Health. Springer Science & Business Media. 2000.
24.
R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2021.
25.
Plummer  M. JAGS: a program for analysis of Bayesian graphical models using Gibbs sampling. Proceedings of the 3rd International Workshop on Distributed Statistical Computing. 2003;124(125.10):1-10.
26.
Liu  Y , Yan  LM , Wan  L ,  et al.  Viral dynamics in mild and severe cases of COVID-19.   Lancet Infect Dis. 2020;20(6):656-657. doi:10.1016/S1473-3099(20)30232-2 PubMedGoogle ScholarCrossref
27.
Yilmaz  A , Marklund  E , Andersson  M ,  et al.  Upper respiratory tract levels of severe acute respiratory syndrome coronavirus 2 RNA and duration of viral RNA shedding do not differ between patients with mild and severe/critical coronavirus disease 2019.   J Infect Dis. 2021;223(1):15-18. doi:10.1093/infdis/jiaa632 PubMedGoogle ScholarCrossref
28.
Kissler  SM , Fauver  JR , Mack  C ,  et al.  Viral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and public health strategies.   PLoS Biol. 2021;19(7):e3001333. doi:10.1371/journal.pbio.3001333 PubMedGoogle Scholar
29.
He  X , Lau  EHY , Wu  P ,  et al.  Temporal dynamics in viral shedding and transmissibility of COVID-19.   Nat Med. 2020;26(5):672-675. doi:10.1038/s41591-020-0869-5 PubMedGoogle ScholarCrossref
30.
Fontana  LM , Villamagna  AH , Sikka  MK , McGregor  JC .  Understanding viral shedding of severe acute respiratory coronavirus virus 2 (SARS-CoV-2): review of current literature.   Infect Control Hosp Epidemiol . 2021;42(6):659-668. doi:10.1017/ice.2020.1273PubMedGoogle Scholar
31.
Lee  S , Kim  T , Lee  E ,  et al.  Clinical course and molecular viral shedding among asymptomatic and symptomatic patients with SARS-CoV-2 infection in a community treatment center in the Republic of Korea.   JAMA Intern Med. 2020;180(11):1447-1452. doi:10.1001/jamainternmed.2020.3862 PubMedGoogle ScholarCrossref
32.
Li  W , Su  YY , Zhi  SS ,  et al.  Virus shedding dynamics in asymptomatic and mildly symptomatic patients infected with SARS-CoV-2.   Clin Microbiol Infect. 2020;26(11):1556.e1-1556.e6. doi:10.1016/j.cmi.2020.07.008 PubMedGoogle ScholarCrossref
33.
Hu  Z , Song  C , Xu  C ,  et al.  Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China.   Sci China Life Sci. 2020;63(5):706-711. doi:10.1007/s11427-020-1661-4 PubMedGoogle ScholarCrossref
34.
McKechnie  JL , Blish  CA .  The innate immune system: fighting on the front lines or fanning the flames of COVID-19?   Cell Host Microbe. 2020;27(6):863-869. doi:10.1016/j.chom.2020.05.009 PubMedGoogle ScholarCrossref
35.
Le Bert  N , Tan  AT , Kunasegaran  K ,  et al.  SARS-CoV-2–specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.   Nature. 2020;584(7821):457-462. doi:10.1038/s41586-020-2550-z PubMedGoogle ScholarCrossref
36.
Sette  A , Crotty  S .  Pre-existing immunity to SARS-CoV-2: the knowns and unknowns.   Nat Rev Immunol. 2020;20(8):457-458. doi:10.1038/s41577-020-0389-z PubMedGoogle ScholarCrossref
37.
Ng  KW , Faulkner  N , Cornish  GH ,  et al.  Preexisting and de novo humoral immunity to SARS-CoV-2 in humans.   Science. 2020;370(6522):1339-1343. doi:10.1126/science.abe1107 PubMedGoogle ScholarCrossref
38.
Tillett  RL , Sevinsky  JR , Hartley  PD ,  et al.  Genomic evidence for reinfection with SARS-CoV-2: a case study.   Lancet Infect Dis. 2021;21(1):52-58. doi:10.1016/S1473-3099(20)30764-7 PubMedGoogle ScholarCrossref
39.
To  KK-W , Hung  IFN , Ip  JD ,  et al.  Coronavirus disease 2019 (COVID-19) re-infection by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 strain confirmed by whole genome sequencing.   Clin Infect Dis. 2021;73(9):e2946-e2951. doi:10.1093/cid/ciaa1275PubMedGoogle Scholar
40.
Galanti  M , Shaman  J .  Direct observation of repeated infections with endemic coronaviruses.   J Infect Dis. 2021;223(3):409-415. doi:10.1093/infdis/jiaa392 PubMedGoogle ScholarCrossref
41.
Waghmare  A , Krantz  EM , Baral  S ,  et al. Reliability of self-sampling for accurate assessment of respiratory virus viral and immunologic kinetics. medRxiv. Preprint posted online April 6, 2020. doi:10.1101/2020.04.03.20051706
42.
Schiffer  JT , Wald  A , Selke  S , Corey  L , Magaret  A .  The kinetics of mucosal herpes simplex virus–2 infection in humans: evidence for rapid viral-host interactions.   J Infect Dis. 2011;204(4):554-561. doi:10.1093/infdis/jir314 PubMedGoogle ScholarCrossref
43.
Schiffer  JT , Swan  DA , Corey  L , Wald  A .  Rapid viral expansion and short drug half-life explain the incomplete effectiveness of current herpes simplex virus 2–directed antiviral agents.   Antimicrob Agents Chemother. 2013;57(12):5820-5829. doi:10.1128/AAC.01114-13 PubMedGoogle ScholarCrossref
44.
Goyal  A , Cardozo-Ojeda  EF , Schiffer  JT .  Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response.   Sci Adv. 2020;6(47):eabc7112. doi:10.1126/sciadv.abc7112 PubMedGoogle Scholar
45.
Cevik  M , Tate  M , Lloyd  O , Maraolo  AE , Schafers  J , Ho  A .  SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis.   Lancet Microbe. 2021;2(1):e13-e22. doi:10.1016/S2666-5247(20)30172-5 PubMedGoogle ScholarCrossref
46.
Chung  E , Chow  EJ , Wilcox  NC ,  et al.  Comparison of Symptoms and RNA Levels in Children and Adults With SARS-CoV-2 Infection in the Community Setting.   JAMA Pediatr. 2021;175(10):e212025. doi:10.1001/jamapediatrics.2021.2025PubMedGoogle Scholar
47.
Zhou  R , Li  F , Chen  F ,  et al.  Viral dynamics in asymptomatic patients with COVID-19.   Int J Infect Dis. 2020;96:288-290. doi:10.1016/j.ijid.2020.05.030 PubMedGoogle ScholarCrossref
48.
Arons  MM , Hatfield  KM , Reddy  SC ,  et al; Public Health–Seattle and King County and CDC COVID-19 Investigation Team.  Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility.   N Engl J Med. 2020;382(22):2081-2090. doi:10.1056/NEJMoa2008457 PubMedGoogle ScholarCrossref
49.
Marks  M , Millat-Martinez  P , Ouchi  D ,  et al.  Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study.   Lancet Infect Dis. 2021;21(5):629-636. doi:10.1016/S1473-3099(20)30985-3 PubMedGoogle ScholarCrossref
50.
Kidd  M , Richter  A , Best  A ,  et al.  S-variant SARS-CoV-2 is associated with significantly higher viral loads in samples tested by ThermoFisher TaqPath RT-QPCR.   J Infect Dis. 2021;223(10):1666-1670. doi:10.1093/infdis/jiab082 PubMedGoogle ScholarCrossref
51.
Frampton  D , Rampling  T , Cross  A ,  et al.  Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study.   Lancet Infect Dis. 2021;21(9):1246-1256. doi:10.1016/S1473-3099(21)00170-5 PubMedGoogle ScholarCrossref
52.
McCulloch  DJ , Kim  AE , Wilcox  NC ,  et al.  Comparison of unsupervised home self-collected midnasal swabs with clinician-collected nasopharyngeal swabs for detection of SARS-CoV-2 infection.   JAMA Netw Open. 2020;3(7):e2016382. doi:10.1001/jamanetworkopen.2020.16382 PubMedGoogle Scholar
53.
Chu  HY , Englund  JA , Starita  LM ,  et al; Seattle Flu Study Investigators.  Early detection of Covid-19 through a citywide pandemic surveillance platform.   N Engl J Med. 2020;383(2):185-187. doi:10.1056/NEJMc2008646 PubMedGoogle ScholarCrossref
Want full access to the AMA Ed Hub?
Become an AMA member now
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
Become an AMA member now
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Privacy Policy|Terms of Use
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue